GlobeNewswire Inc. · Feb 12, 2024
Freeline Shareholders Approve Acquisition by Syncona
Freeline Shareholders Approve Acquisition by Syncona
FR
NASDAQ · FRLN
Freeline Therapeutics Holdings plc
Healthcare · Biotechnology
$6.49
Up+$0.01 (+0.15%)
Updated Aug 25, 2026, 12:11 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 28.28M
- P/E ratio
- -0.29
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 5.35K
- Avg. volume
- 12.27K
Price performance
FRLN price history
1M range · 0 trading sessions · Daily adjusted prices
FRLN does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest FRLN news
The latest Smart Investors Daily articles mentioning FRLN.
Stock researchCompany · Overview
FRLN research
Overview
Company profile and research snapshot.
Company profile
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 28, 2023 | HC Wainwright & Co. | Neutral | — |
| Oct 18, 2023 | Wedbush | Neutral | — |
| Aug 17, 2023 | HC Wainwright & Co. | Buy | — |
| Aug 16, 2023 | Stifel | Hold | — |
| Aug 1, 2023 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Zacks Investment Research · Nov 23, 2023
Freeline (FRLN) Shares Rise on Merger Agreement With Syncona
Freeline Therapeutics (FRLN) is set to be acquired by Syncona Ltd. The transaction is expected to be closed in the first quarter of 2024. Shares rise.
GlobeNewswire Inc. · Nov 22, 2023
Syncona to Acquire Freeline Therapeutics
Syncona to Acquire Freeline Therapeutics
GlobeNewswire Inc. · Oct 25, 2023
Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress
Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Con
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
